CVS HEALTH CORPORATION (CVS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.17%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.17% | Share-based compensation / revenue. Period ending 2026-06-30. $715.00M ÷ $415.09B × 100 ≈ 0.17% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 415.09B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 715.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 8.29B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $415.09B | $715.00M | $8.29B | (m) | (m) | 0.17% | (m) | (m) |
| 2026-03-31 | (m) | $407.90B | $675.00M | $5.97B | (m) | (m) | 0.17% | (m) | (m) |
| 2025-12-31 | (m) | $402.07B | $535.00M | $4.66B | (m) | (m) | 0.13% | (m) | (m) |
| 2025-09-30 | (m) | $394.08B | $537.00M | $4.92B | (m) | (m) | 0.14% | (m) | (m) |
| 2025-06-30 | (m) | $386.64B | $532.00M | $8.96B | (m) | (m) | 0.14% | (m) | (m) |
| 2025-03-31 | (m) | $378.96B | $529.00M | $9.62B | (m) | (m) | 0.14% | (m) | (m) |
| 2024-12-31 | (m) | $372.81B | $540.00M | $8.52B | (m) | (m) | 0.14% | (m) | (m) |
| 2024-09-30 | (m) | $368.91B | $530.00M | $9.52B | (m) | (m) | 0.14% | (m) | (m) |
| 2024-06-30 | (m) | $363.25B | $551.00M | $12.38B | (m) | (m) | 0.15% | (m) | (m) |
| 2024-03-31 | (m) | $360.94B | $622.00M | $12.57B | $2.79B | (m) | 0.17% | 4.51× | Reported |
| 2023-12-31 | (m) | $357.78B | $588.00M | $13.74B | $2.66B | (m) | 0.16% | 5.17× | Reported |
| 2023-09-30 | (m) | $347.81B | $567.00M | $14.03B | $2.52B | (m) | 0.16% | 5.57× | Reported |
| 2023-06-30 | (m) | $339.20B | $518.00M | $6.42B | $2.39B | (m) | 0.15% | 2.68× | Reported |
| 2023-03-31 | (m) | $330.92B | $461.00M | $7.65B | $2.29B | (m) | 0.14% | 3.34× | Reported |
| 2022-12-31 | (m) | $322.47B | $447.00M | $7.75B | $2.29B | (m) | 0.14% | 3.39× | Reported |
| 2022-09-30 | (m) | $315.23B | $479.00M | $6.36B | $2.34B | (m) | 0.15% | 2.71× | Reported |
| 2022-06-30 | (m) | $307.86B | $488.00M | $13.35B | $2.38B | (m) | 0.16% | 5.61× | Reported |
| 2022-03-31 | (m) | $299.84B | $486.00M | $13.11B | $2.43B | (m) | 0.16% | 5.39× | Reported |
| 2021-12-31 | (m) | $292.11B | $484.00M | $13.19B | $2.50B | (m) | 0.17% | 5.27× | Reported |
| 2021-09-30 | (m) | $285.06B | $458.00M | $13.49B | $2.57B | (m) | 0.16% | 5.24× | Reported |
| 2021-06-30 | (m) | $278.32B | $453.00M | $13.68B | $2.70B | (m) | 0.16% | 5.06× | Reported |
| 2021-03-31 | (m) | $271.05B | $391.00M | $14.03B | $2.83B | (m) | 0.14% | 4.96× | Reported |
| 2020-12-31 | (m) | $268.71B | $400.00M | $13.91B | $2.91B | (m) | 0.15% | 4.79× | Reported |
| 2020-09-30 | (m) | $266.85B | $386.00M | $14.42B | $2.96B | (m) | 0.14% | 4.87× | Reported |
| 2020-06-30 | (m) | $264.34B | $406.00M | $14.10B | $2.98B | (m) | 0.15% | 4.73× | Reported |
| 2020-03-31 | (m) | $262.13B | $435.00M | $12.76B | $2.99B | (m) | 0.17% | 4.27× | Reported |
| 2019-12-31 | (m) | $256.78B | $453.00M | $11.99B | $3.04B | (m) | 0.18% | 3.95× | Reported |
| 2019-09-30 | (m) | $243.33B | $463.00M | $9.77B | $3.03B | (m) | 0.19% | 3.22× | Reported |
| 2019-06-30 | (m) | $226.05B | $396.00M | $9.42B | $2.96B | (m) | 0.18% | 3.18× | Reported |
| 2019-03-31 | (m) | $209.62B | $339.00M | $4.71B | $2.88B | (m) | 0.16% | 1.64× | Reported |
| 2018-12-31 | (m) | $193.92B | $280.00M | $4.02B | $2.62B | (m) | 0.14% | 1.54× | Reported |
| 2018-09-30 | (m) | $188.06B | $233.00M | $5.82B | (m) | (m) | 0.12% | (m) | (m) |
| 2018-06-30 | (m) | $186.97B | $236.00M | $5.97B | (m) | (m) | 0.13% | (m) | (m) |
| 2018-03-31 | (m) | $185.94B | $234.00M | $9.67B | (m) | (m) | 0.13% | (m) | (m) |
| 2017-12-31 | (m) | $184.76B | $234.00M | $9.52B | $1.06B | (m) | 0.13% | 8.96× | Reported |
| 2017-09-30 | (m) | $182.35B | $229.00M | $9.38B | (m) | (m) | 0.13% | (m) | (m) |
| 2017-06-30 | (m) | $180.78B | $223.00M | $9.71B | (m) | (m) | 0.12% | (m) | (m) |
| 2017-03-31 | (m) | $178.82B | $220.00M | $9.95B | (m) | (m) | 0.12% | (m) | (m) |
| 2016-12-31 | (m) | $177.53B | $222.00M | $10.34B | $1.08B | (m) | 0.13% | 9.59× | Reported |
| 2016-09-30 | (m) | $172.70B | $221.00M | $10.07B | $1.11B | (m) | 0.13% | 9.06× | Reported |
| 2016-06-30 | (m) | $166.73B | $249.00M | $9.59B | $1.12B | (m) | 0.15% | 8.54× | Reported |
| 2016-03-31 | (m) | $160.17B | $243.00M | $9.50B | $1.01B | (m) | 0.15% | 9.40× | Reported |
| 2015-12-31 | (m) | $153.29B | $230.00M | $9.45B | $859.00M | (m) | 0.15% | 11.01× | Reported |
| 2015-09-30 | (m) | $149.20B | $219.00M | $9.05B | $712.00M | (m) | 0.15% | 12.71× | Reported |
| 2015-06-30 | (m) | $145.58B | $176.00M | $8.96B | $602.00M | (m) | 0.12% | 14.89× | Reported |
| 2015-03-31 | (m) | $143.01B | $174.00M | $8.91B | $591.00M | (m) | 0.12% | 15.07× | Reported |
| 2014-12-31 | (m) | $139.37B | $165.00M | $8.80B | $615.00M | (m) | 0.12% | 14.31× | Reported |
| 2014-09-30 | (m) | $135.14B | $161.00M | $8.70B | $618.00M | (m) | 0.12% | 14.07× | Reported |
| 2014-06-30 | (m) | $132.05B | $152.00M | $8.60B | $585.00M | (m) | 0.12% | 14.71× | Reported |
| 2014-03-31 | (m) | $128.70B | $142.00M | $8.37B | $551.00M | (m) | 0.11% | 15.19× | Reported |
| 2013-12-31 | (m) | $126.76B | $141.00M | $8.04B | $517.00M | (m) | 0.11% | 15.55× | Reported |
| 2013-09-30 | (m) | $125.37B | $136.00M | $8.13B | $541.00M | (m) | 0.11% | 15.03× | Reported |
| 2013-06-30 | (m) | $123.63B | $134.00M | $7.78B | $551.00M | (m) | 0.11% | 14.13× | Reported |
| 2013-03-31 | (m) | $123.10B | $130.00M | $7.52B | $555.00M | (m) | 0.11% | 13.55× | Reported |
| 2012-12-31 | (m) | $123.13B | $132.00M | $7.23B | $561.00M | (m) | 0.11% | 12.88× | Reported |
| 2012-09-30 | (m) | $120.06B | $132.00M | $6.88B | $547.00M | (m) | 0.11% | 12.58× | Reported |
| 2012-06-30 | (m) | $116.50B | $134.00M | $6.65B | $568.00M | (m) | 0.12% | 11.71× | Reported |
| 2012-03-31 | (m) | $112.20B | $135.00M | $6.43B | $586.00M | (m) | 0.12% | 10.97× | Reported |
| 2011-12-31 | (m) | $107.10B | $135.00M | $6.33B | $588.00M | (m) | 0.13% | 10.77× | Reported |
| 2011-09-30 | (m) | $104.01B | $138.00M | $6.16B | $577.00M | (m) | 0.13% | 10.68× | Reported |
| 2011-06-30 | (m) | $101.16B | $140.00M | $6.05B | $558.00M | (m) | 0.14% | 10.85× | Reported |
| 2011-03-31 | (m) | $98.53B | $149.00M | $6.07B | $545.00M | (m) | 0.15% | 11.13× | Reported |
| 2010-12-31 | (m) | $96.41B | $150.00M | $6.17B | $539.00M | (m) | 0.16% | 11.44× | Reported |
| 2010-09-30 | (m) | $97.46B | $164.00M | $6.29B | (m) | (m) | 0.17% | (m) | (m) |
| 2010-06-30 | (m) | $98.23B | $165.00M | $6.37B | (m) | (m) | 0.17% | (m) | (m) |
| 2010-03-31 | (m) | $99.09B | $180.00M | $6.47B | (m) | (m) | 0.18% | (m) | (m) |
| 2009-12-31 | (m) | $98.73B | $165.00M | $6.44B | (m) | (m) | 0.17% | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $87.47B | $92.00M | $6.05B | (m) | (m) | 0.11% | (m) | (m) |
| 2008-09-27 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-29 | (m) | $76.33B | $78.00M | $4.79B | (m) | (m) | 0.10% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PETMED EXPRESS INC (PETS) | United States | $0.034B | -1.41 |